LMLuca Maccioni

Luca Maccioni

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Luca Maccioni has a total of 48 co-authors. Here are the top co-authors by number of shared publications:

  • Bin Gao

    Laboratory of Liver Diseases, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD, USA.

    8 shared publications
  • Bryan Mackowiak

    Laboratory of Liver Diseases, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD, USA

    3 shared publications
  • Dechun Feng

    Laboratory of Liver Diseases, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD, USA

    3 shared publications
  • Yang Wang

    Laboratory of Liver Diseases, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Maryland, USA

    3 shared publications
  • Yaojie Fu

    Laboratory of Liver Diseases, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, USA

    3 shared publications
  • Yukun Guan

    Laboratory of Liver Diseases, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Maryland, USA

    3 shared publications

Latest Publications

  • Liver as a key organ for systemic antimicrobial defense

    by Tiantian Yao, Luca Maccioni, Yukun Guan, Robim M. Rodrigues, Bin Gao

    Chronic liver disease (CLD) is a progressive condition marked by persistent inflammation and regeneration of hepatic tissue, often leading to cirrhosis and increased susceptibility to microbial infections. These infections not only trigger acute decompensation and acute-on-chronic liver failure but also contribute to poor clinical outcomes despite antibiotic treatment. Conversely, CLD itself exacerbates infection severity, forming a vicious cycle. Recent research has highlighted the diverse and coordinated roles of liver parenchymal and nonparenchymal cells in antimicrobial immunity. Hepatocytes control infection by producing a large number of antimicrobial peptides, opsonins, and inflammatory mediators. KCs are key to capturing and clearing blood-borne pathogens and orchestrating immune responses. LSECs facilitate immune cell trafficking, pathogen sensing, and modulation of neutrophil-mediated defense. HSCs are activated during bacterial infections and promote fibrosis through inflammasome and TGF-β signaling. Biliary epithelial cells serve as frontline defenders in the biliary tract, expressing pattern recognition receptors and secreting cytokines, chemokines, defensins, and IgA. Understanding the complex interplay between hepatocytes, liver nonparenchymal cells, and immune components is crucial for developing targeted therapies to improve infection control and outcomes in patients with chronic liver disease. Here, we provide a comprehensive summary of the roles played by different hepatic cell types during microbial infections with a focus on bacterial infection. The potential mechanisms underlying the increased susceptibility of CLDs to these infections are also briefly discussed.


  • Open Access

    Serum Metabolite Profile in Progressive Versus Nonprogressive Alcohol‐Related Liver Disease: A Cross‐Sectional Metabolomics Study

    by Eemeli Puhakka, Hany Ahmed, Retu Haikonen, Sophie Leclercq, Kati Hanhineva, Luca Maccioni, Camille Amadieu, Marko Lehtonen, Ville Männistö, Jaana Rysä, et al.

    Background and Aims: Alcohol‐related liver disease (ALD) is a major cause of mortality and disability‐adjusted life years. It is not fully understood why a small proportion of patients develop progressive forms of ALD (e.g., fibrosis and cirrhosis). Differences in the metabolic processes could be behind the individual progression of ALD. Our aim was to examine differences in serum metabolome between patients with nonprogressive ALD and patients with an early form of progressive ALD.Methods: The study had three study groups: progressive ALD (alcohol‐related steatohepatitis or early‐stage fibrosis, n = 50), nonprogressive ALD (simple steatosis, n = 50) and healthy controls (n = 32). Both ALD groups took part in a voluntary alcohol rehabilitation programme. A nontargeted metabolomics analysis and targeted analysis of short‐chain fatty acids were done to the serum samples taken on the day of admission.Results: We found 111 significantly (p < 0.0005) altered identified metabolites between the study groups. Our main finding was that levels of glycine‐conjugated bile acids (Cohen's d = 0.90–0.91), glutamic acid (d = 1.01), 7‐methylguanine (d = 0.77) and several phosphatidylcholines (d = 0.61–0.85) were elevated in the progressive ALD group in comparison to the nonprogressive ALD group. Glycine‐conjugated bile acids, glutamic acid and 7‐methylguanine also positively correlated with increased levels of aspartate aminotransferase, alanine aminotransferase, gamma‐glutamyl transferase, cell death biomarker M65 and liver stiffness.Conclusions: Our results indicate that the enterohepatic cycle of glycine‐conjugated bile acids, as well as lipid and energy metabolism, is altered in early forms of progressive ALD. These metabolic processes could be a target for preventing the progression of ALD.


  • Opposite regulation of intestinal and intrahepatic CD8 + T cells controls alcohol-associated liver disease progression

    by Luca Maccioni, Yukun Guan, Mariia Kim, Maria A Parra, Brandon Peiffer, Yaojie Fu, Yang Wang, Yu-Hong Lin, Bryan Mackowiak, Dechun Feng, et al.

    Background: Gut-liver crosstalk plays an important role in alcohol-associated liver disease (ALD) pathogenesis; but underlying mechanisms remain obscure. Objective: We examined the regulation of intestinal and intrahepatic CD8 + T lymphocytes and their contribution to ALD. Design: ALD patients were recruited for evaluation of intestinal and liver T cells. Single-cell RNA sequencing (scRNA seq) was performed to analyse intrahepatic and peripheral T cells in ALD. Wildtype, CD8-specific Bcl2 transgenic ( Cd8 Bcl-2 ), and Cd8 −/− mice were subjected to chronic-plus-binge ethanol feeding. Results: In ALD patients, duodenal CD8 + T cells were selectively reduced and negatively correlated with liver injury and bacterial translocation markers, while intrahepatic CD8 + T cells were markedly increased. ScRNA seq analysis of ALD patient livers revealed several populations of CD8 + T cells expressing activation and survival genes (eg, Bcl2 ). Transcriptomics and functional studies revealed a key role of prosurvival BCL2 in this opposite regulation of CD8 + T cells. Mechanistically, chronic-plus-binge ethanol feeding reduced CD8 + T cells specifically in the duodenum where ethanol levels are high. Inducing BCL2 in CD8 + T cells reversed ethanol-induced loss of duodenal CD8 + T cells, improved gut barrier function and ameliorated ALD, while CD8 deficiency was linked to enhanced neutrophil and macrophage infiltration in the liver, exacerbating ALD in mice. Conclusions: ALD is associated with loss of duodenal CD8 + T cells but elevation of intrahepatic CD8 + T cells, which aggravates and ameliorates ALD, respectively. Restoration of survival and functions of intestinal and intrahepatic CD8 + T cells may represent a novel therapeutic strategy for ALD patients.


  • Open Access

    Characterisation of macrophages in healthy and diseased livers in mice: identification of necrotic lesion-associated macrophages

    by Dechun Feng, Yukun Guan, Yang Wang, Luca Maccioni, Bryan Mackowiak, Bin Gao

    Background: Healthy livers contain a large number of resident macrophages named Kupffer cells (KCs), which are partially replaced by infiltrating monocyte-derived macrophages (MoMFs) during acute or chronic liver injury. Despite extensive research, understanding macrophage heterogeneity, spatial distribution and interactions with other cells within the liver remains challenging. Methods: This study employs sequential multiplex immunofluorescence staining, advanced image analysis and single-cell RNA sequencing (scRNA-seq) analysis to characterise macrophages in both healthy and diseased livers in mice. Results: Our data revealed that liver KCs made up more than 80% of total immune cells in healthy mouse livers, while massive amounts of MoMFs infiltrated into the livers after acute and chronic liver injury. KCs were more abundant and larger in Zones 1 and 2 compared with Zone 3 in healthy livers. Zone 1 KCs exhibited higher phagocytic activity than Zone 2/3 KCs and MoMFs. We simultaneously evaluated cell proliferation and apoptosis on one slide and found that proliferation and apoptosis of KCs and MoMFs significantly increased in acutely injured livers. We also performed scRNA-seq to investigate liver macrophage gene expression in naïve and concanavalin A (ConA)-treated mice. MoMF clusters expanded following ConA treatment, while KCs remained stable. Macrophages were divided into distinct subtypes, including C1q+ MoMFs, with differential expression of genes like Trem2, Spp1, Fabp5 and Gpnmb. Newly recruited C1q− MoMFs expressed high levels of Lyz and Ccr2, while Itgax (Cd11c)+ MoMFs expressed endothelin converting enzyme 1 (Ece1), a gene encoding ECE1 enzyme that activates endothelin to promote hepatic stellate cell contraction and necrotic lesion resolution. By immunostaining analysis of the proteins encoded by these signature genes, we identified several populations of MoMFs that were mainly located surrounding the necrotic lesion area and expressed various proteins that are involved in dead cell debris clearance. Conclusion: We developed a robust framework for studying liver macrophages in vivo, offering insights into their roles in host defence and liver injury/repair. We identified several populations of MoMFs that surround necrotic lesion areas and express proteins that promote dead cell debris clearance. These necrotic lesion-associated macrophages likely play key roles in promoting necrotic lesion resolution.


  • Open Access

    Gut cannabinoid receptor 1 regulates alcohol binge-induced intestinal permeability

    by Luca Maccioni, Szabolcs Dvorácskó, Grzegorz Godlewski, Resat Cinar, Malliga R Iyer, Bin Gao, George Kunos

    Background: Endocannabinoids acting via cannabinoid receptor 1 (CB1R) can elicit increased intestinal permeability (a condition also called ‘leaky gut’). Alcohol binge can adversely affect digestive functions, including intestinal permeability; however, the underlying mechanisms remain incompletely understood. The current study aimed at examining whether CB1R is involved in alcohol binge-induced intestinal permeability. Methods: We developed intestinal epithelial-specific CB1R knockout (CB1IEC−/−) mice and evaluated the in vivo contribution of gut CB1R in alcohol binge-induced intestinal permeability. Results: Alcohol binge increased anandamide levels in the proximal small intestine in association with increased intestinal permeability. Radioligand binding and functional assays confirmed that the genetic deletion of intestinal epithelial CB1R did not alter the density or functionality of CB1R in the brain. Additionally, a peripheral CB1R antagonist, (S)-MRI-1891 (INV-202/monlunabant), exhibited comparable binding affinity to CB1R in brain homogenates. An acute oral administration of (S)-MRI-1891 (3 mg/kg) reduced alcohol binge-induced intestinal permeability in littermate control CB1f/f (CB1 floxed/floxed) mice but had no effect in CB1IEC−/− mice, underscoring the role of intestinal CB1R in this phenomenon. Mechanistically, we found that alcohol activated intestinal epithelial CB1R-ERK1/2 pathway with subsequent downregulation of tight junction proteins and reduction in villi length. In addition, targeting intestinal CB1R and downstream ERK1/2 was able to reverse this process, with subsequent upregulation of tight junction proteins and increased villi length, thus improving gut barrier function. Despite the effects on intestinal permeability, deletion of intestinal CB1R did not significantly affect metabolic parameters and liver disease. Conclusion: Our findings suggest that alcohol promotes leaky gut via the activation of gut epithelial CB1R and demonstrate that inhibition of CB1R with peripheral-restricted selective CB1R antagonists can prevent alcohol binge-induced intestinal permeability.


  • Open Access

    New therapeutic target for alcohol-associated hepatitis (AH): AH-associated IL-8+ neutrophils

    by Yukun Guan, Dechun Feng, Luca Maccioni, Yang Wang, Bin Gao

    Alcohol-associated liver disease (ALD) is one of the leading chronic liver diseases worldwide, encompassing a spectrum of conditions from simple steatosis to steatohepatitis, cirrhosis, and hepatocellular carcinoma.1 Histologically, alcohol-associated steatohepatitis (ASH) is characterised by lipid accumulation in hepatocytes, hepatocellular damage, ballooning of hepatocytes, formation of Mallory-Denk bodies, inflammation and pericellular fibrosis.1 Over the past several decades, research has elucidated key molecular mechanisms underlying ALD, such as ethanol-induced hepatotoxicity, oxidative stress, endoplasmic reticulum stress and organ–organ crosstalk pathways like the gut-liver and adipose tissue-liver axes.2 Patients with underlying chronic ALD, particularly those with recent episodes of excessive drinking, are at risk of developing acute alcohol-associated hepatitis (AH), a condition characterised by severe clinical symptoms, including jaundice.3 Severe AH (sAH) is commonly linked to alcohol-associated cirrhosis (AC) and carries a high short-term mortality rate. Due to the limited availability of effective pharmacological therapies, early liver transplantation is frequently required as a life-saving intervention.3 Identifying molecular mechanisms driving AH progression and liver failure is thus essential for developing targeted therapies for this life-threatening disease. AH, first described in 1961, is recognised as an acute inflammatory liver disease characterised by extensive inflammatory cell infiltration.4 Currently, AH is recognised as a form of acute-on-chronic liver injury involving various types of immune cells, including macrophages, neutrophils, T cells and B cells, as evidenced by immunohistochemical analysis.5 Recent RNA-sequencing analyses have highlighted that AH is associated with the upregulation of numerous inflammatory mediators, including pro-inflammatory cytokines, chemokines and adhesion molecules.5–7 However, the key mechanisms that drive the transition from ALD to sAH remain unclear.


  • Open Access

    Differences in the serum metabolomic profile of progressive alcohol-related liver disease in comparison to non-progressive alcohol-related liver disease: a cross sectional metabolomics study

    by Eemeli Puhakka, Hany Ahmed, Retu Haikonen, Sophie Leclercq, Kati Hanhineva, Luca Maccioni, Camille Amadieu, Marko Lehtonen, Ville Männistö, Jaana Rysä, et al.

    Alcohol-related liver disease (ALD) is a major cause of mortality and disability adjusted life years. It is not fully understood why a small proportion of patients develop progressive forms of ALD (e.g. fibrosis, cirrhosis). Differences in the metabolic processes could be behind the individual progression of ALD. Our aim was to examine differences in serum metabolome between patients with non-progressive ALD and patients with an early form of progressive ALD. The study had three study groups: progressive ALD (alcohol-related steatohepatitis or early-stage fibrosis, n=50), non-progressive ALD (simple steatosis, n=50) and healthy controls (n=32). Both ALD groups took part in a voluntary alcohol rehabilitation program. A non-targeted metabolomics analysis and targeted analysis of short chain fatty acids was done to the serum samples taken on the day of admission. We found 111 significantly (p<0.0005) altered identified metabolites between the study groups. Our main finding was that levels of glycine conjugated bile acids, glutamic acid, 7-methylguanine and several phosphatidylcholines were elevated in the progressive ALD group in comparison to both the non-progressive ALD group and the controls. Glycine conjugated bile acid, glutamic acid and 7-methylguanine also positively correlated with increased levels of aspartate aminotransferase, alanine aminotransferase, gamma-glutamyl transferase, cell death biomarker M65, and liver stiffness. Our results indicate that the enterohepatic cycle of glycine conjugated bile acids as well as lipid and energy metabolism are altered in early forms of progressive ALD. These metabolic processes could be a target for preventing progression of ALD.

  • Top Cited Papers

    Coordinated action of a gut–liver pathway drives alcohol detoxification and consumption

    by Yaojie Fu, Bryan Mackowiak, Yu-Hong Lin, Luca Maccioni, Taylor Lehner, Hongna Pan, Yukun Guan, Grzegorz Godlewski, Hongkun Lu, Cheng Chen, et al.

    Alcohol use disorder (AUD) affects millions of people worldwide, causing extensive morbidity and mortality with limited pharmacological treatments. The liver is considered as the principal site for the detoxification of ethanol metabolite, acetaldehyde (AcH), by aldehyde dehydrogenase 2 (ALDH2) and as a target for AUD treatment, however, our recent data indicate that the liver only plays a partial role in clearing systemic AcH. Here we show that a liver–gut axis, rather than liver alone, synergistically drives systemic AcH clearance and voluntary alcohol drinking. Mechanistically, we find that after ethanol intake, a substantial proportion of AcH generated in the liver is excreted via the bile into the gastrointestinal tract where AcH is further metabolized by gut ALDH2. Modulating bile flow significantly affects serum AcH level and drinking behaviour. Thus, combined targeting of liver and gut ALDH2, and manipulation of bile flow and secretion are potential therapeutic strategies to treat AUD.


  • Top Cited Papers

    Alcohol-associated liver cancer

    by Yaojie Fu, Luca Maccioni, Xin Wei Wang, Tim F. Greten, Bin Gao

    Heavy alcohol intake induces a wide spectrum of liver diseases ranging from steatosis, steatohepatitis, cirrhosis, and HCC. Although alcohol consumption is a well-known risk factor for the development, morbidity, and mortality of HCC globally, alcohol-associated hepatocellular carcinoma (A-HCC) is poorly characterized compared to viral hepatitis–associated HCC. Most A-HCCs develop after alcohol-associated cirrhosis (AC), but the direct carcinogenesis from ethanol and its metabolites to A-HCC remains obscure. The differences between A-HCC and HCCs caused by other etiologies have not been well investigated in terms of clinical prognosis, genetic or epigenetic landscape, molecular mechanisms, and heterogeneity. Moreover, there is a huge gap between basic research and clinical practice due to the lack of preclinical models of A-HCC. In the current review, we discuss the pathogenesis, heterogeneity, preclinical approaches, epigenetic, and genetic profiles of A-HCC, and discuss the current insights into and the prospects for future research on A-HCC. The potential effect of alcohol on cholangiocarcinoma and liver metastasis is also discussed.


  • Top Cited Papers
    Open Access

    Alcohol-associated liver disease

    by Bryan Mackowiak, Yaojie Fu, Luca Maccioni, Bin Gao

    Alcohol-associated liver disease (ALD) is a major cause of chronic liver disease worldwide, and comprises a spectrum of several different disorders, including simple steatosis, steatohepatitis, cirrhosis, and superimposed hepatocellular carcinoma. Although tremendous progress has been made in the field of ALD over the last 20 years, the pathogenesis of ALD remains obscure, and there are currently no FDA-approved drugs for the treatment of ALD. In this Review, we discuss new insights into the pathogenesis and therapeutic targets of ALD, utilizing the study of multiomics and other cutting-edge approaches. The potential translation of these studies into clinical practice and therapy is deliberated. We also discuss preclinical models of ALD, interplay of ALD and metabolic dysfunction, alcohol-associated liver cancer, the heterogeneity of ALD, and some potential translational research prospects for ALD.